US FDA approves Menveo in a new single-vial presentation to help ... - GSK
Oct 17, 2022 · The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation will initially be available to US federal customers, with broader availability anticipated in mid-2023.
Menveo New Ready-to-Use Single Vial Presentation Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by . Neisseria meningitidis. serogroups . A, C, Y, and W. Menveo is now available in two presentations: • Two-vial (requires reconstitution) Recommended for ages 2 months and older* • Single-vial ...
FDA Approves Menveo Single-Vial Presentation for Disease …
Oct 17, 2022 · New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Single-Vial Presentation of Meningococcal Vaccine Menveo Gets …
Oct 17, 2022 · The FDA has approved a new ready-to-use single dose vial presentation of Menveo for active immunization against invasive meningococcal disease.
MENVEO | FDA - U.S. Food and Drug Administration
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
GSK announces first participant vaccinated in phase 3 clinical …
Aug 19, 2020 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase III clinical programme investigating its 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo.
ACIP Updates Recommendations for Meningococcal Vaccination
Oct 7, 2020 · Three MenACWY vaccines are licensed for use in the United States: Menactra (for persons age 9 months to 55 years), Menveo (for those age 2 months to 55 years) and MenQuadfi (for those age 2 years...
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of ...
Sep 15, 2022 · Phase 3 trial demonstrates that the investigational pentavalent meningococcal vaccine (MenABCWY) was well-tolerated with an acceptable safety profile and immunogenicity non-inferior to Trumenba ® + Menveo ® for all serogroups
Novartis Receives FDA Approval of Menveo(R), a Vaccine to …
Feb 22, 2010 · FDA approval of Menveo was based on a Phase III head-to-head clinical trial that compared Menveo to the other US-licensed ACWY meningococcal conjugate vaccine among subjects 11 to 55 years of age.
Discover MENVEO | MENVEO [Meningococcal (Groups A, C, Y and …
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.